Design Therapeutics annual return on equity
2021
2022
2023
2024
2025
Design Therapeutics Return on Equity (ROE) Growth & History (DSGN)
Design Therapeutics's return on equity was −30.70% for fiscal 2025.
View full Design Therapeutics company overviewDesign Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −30.70% | −11.62 pp |
| 2024 | 2024-12-31 | −19.08% | +3.02 pp |
| 2023 | 2023-12-31 | −22.10% | −4.26 pp |
| 2022 | 2022-12-31 | −17.85% | +1.32 pp |
| 2021 | 2021-12-31 | −19.16% | — |
Design Therapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −9.60% | −0.95 pp |
| Q1 2026 | 2026-03-31 | −8.19% | −0.65 pp |
| Q4 2025 | 2025-12-31 | −7.76% | −2.24 pp |
| Q3 2025 | 2025-09-30 | −8.24% | −3.16 pp |
| Q2 2025 | 2025-06-30 | −8.66% | −4.21 pp |
| Q1 2025 | 2025-03-31 | −7.54% | −3.48 pp |
| Q4 2024 | 2024-12-31 | −5.52% | −1.31 pp |
| Q3 2024 | 2024-09-30 | −5.08% | +0.35 pp |
| Q2 2024 | 2024-06-30 | −4.44% | +2.10 pp |
| Q1 2024 | 2024-03-31 | −4.06% | +1.97 pp |
| Q4 2023 | 2023-12-31 | −4.21% | +0.98 pp |
| Q3 2023 | 2023-09-30 | −5.43% | −0.36 pp |
| Q2 2023 | 2023-06-30 | −6.54% | −2.42 pp |
| Q1 2023 | 2023-03-31 | −6.03% | −2.50 pp |
| Q4 2022 | 2022-12-31 | −5.19% | −2.33 pp |
| Q3 2022 | 2022-09-30 | −5.07% | −2.22 pp |
| Q2 2022 | 2022-06-30 | −4.12% | −2.24 pp |
| Q1 2022 | 2022-03-31 | −3.53% | −0.75 pp |
| Q4 2021 | 2021-12-31 | −2.86% | — |
| Q3 2021 | 2021-09-30 | −2.85% | — |
| Q2 2021 | 2021-06-30 | −1.89% | — |
| Q1 2021 | 2021-03-31 | −2.78% | — |
Design Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Design Therapeutics's return on equity decreased from −19.16% to −30.70%, a change of −11.54 percentage points. The latest reported quarter, Q2 2026, shows −9.60%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Design Therapeutics source filings ↗